Results 61 to 70 of about 8,294 (239)

Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: the design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial [PDF]

, 2017
Background: Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure.
Braunwald, Eugene, Cirino, Allison L., Colan, Steven D., Day, Sharlene M., Desai, Akshay S., Ho, Carolyn Y., Lipshultz, Steven E., MacRae, Calum A., McMurray, John J.V., Orav, E. John, Shi, Ling, Solomon, Scott D.   +11 more
core   +1 more source

Amine‐Triggered Azabenz‐Annulation of Cyclic Secondary Amine‐Functionalized Perylene Diimides for Dual‐Mode Sensing

Chemistry – A European Journal, EarlyView.
Pictet‐Spengler Intermediate of a cyclic secondary amine perylene diimide undergoing amine‐triggered conversion to azabenz‐annulated perylene diimide, inducing a high‐contrast green‐to‐yellow color change along with fluorescence turn‐on, demonstrating intuitive “safe” to “warning” dual‐mode sensing.
Irene E. Park, Alejandro J. Cuellar de Lucio, Gregory C. Welch   +2 more
wiley   +1 more source

Fully Percutaneous Treatment of LVOT Obstruction and Mitral Regurgitation in a Patient With History of Acromegaly

JACC: Case Reports
Background: We report a 79-year-old woman with congestive heart failure. The patient had a history of acromegaly due to a pituitary macroadenoma. Case Summary: Echocardiography revealed severe mitral regurgitation due to flail of the posterior leaflet ...
Lucca Loretz, MD, Federico Moccetti, MD, Mathias Wolfrum, MD, Bart De Boeck, MD, PhD, Simon Fabian Stämpfli, MD, MSc, Matthias Bossard, MD, Adrian Attinger-Toller, MD, Yves Suter, MD, Florim Cuculi, MD, Stefan Toggweiler, MD   +9 more
doaj   +1 more source

Non-pharmaceutical Interventions for Hypertrophic Cardiomyopathy: A Mini Review

Frontiers in Cardiovascular Medicine, 2021
Hypertrophic cardiomyopathy is an inherited cardiovascular disease, and 70% of patients have left ventricular outflow tract obstruction. Ventricular septal myectomy has been the gold standard treatment for most patients with refractory symptoms.
Miaomiao He, Jie Qiu, Yang Bai, Yan Wang, Mei Hu, Guangzhi Chen   +5 more
doaj   +1 more source

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy [PDF]

Heart, 2006
Hypertrophic cardiomyopathy (HCM) is a genetic condition characterised by the presence of otherwise unexplained left ventricular hypertrophy. The clinical spectrum of the disease is remarkably heterogeneous, ranging from individuals with normal life expectancy and minimal symptoms to those with lives severely restricted by breathlessness and chest pain
openaire   +2 more sources

Expedient Discovery of a Metallaphotoredox Cyanomethylation for Synthesizing α‐Aryl Nitriles

Chemistry – A European Journal, EarlyView.
A metallaphotoredox cyanomethylation reaction has been developed for the synthesis of valuable α‐aryl nitrile intermediates. The methodology was successfully applied to diverse medicinally‐relevant substrates, providing an expedient route to anti‐cancer Senexin compounds, while also removing the need for toxic cyanide reagents. The mechanism was probed
Gemma C. Cook, Blandine McKay, Craig Jamieson, Lee J. Edwards, Charlotte Harriman, Zackary S. Read, Simon T. Bate   +6 more
wiley   +1 more source

Sepsis-induced suicidal left ventricular in a patient with hypertrophic cardiomyopathy/hypertrophic obstructive cardiomyopathy

Apollo Medicine, 2022
Hypertrophic cardiomyopathy is the most common heritable cardiomyopathy, manifesting as left ventricular hypertrophy. In this case, a 48-year-male patient presented with complaints of shortness of breath, uneasiness for 15 days, right lower limb pain ...
K Roshan Rao, Sarita Rao, Ankur Gupta
doaj   +1 more source

Septal myectomy for hypertrophic obstructive cardiomyopathy: coil, boil and the role of rescue surgery [PDF]

, 2017
Interventional treatment of hypertrophic obstructive cardiomyopathy has considerably developed and primary surgical approach is nowadays considered for a minority of patients with insufficient relief of obstruction following catheter intervention.
Carrel, Thierry, Schmidli, Jürg
core  

Biophysical processes of morphogenesis in lizard lungs

Developmental Dynamics, EarlyView.
Abstract Background The lungs of squamate reptiles (lizards and snakes) are highly diverse, exhibiting single chambers, multiple chambers, transitional forms with two to three chambers, along with a suite of other anatomical features, including finger‐like epithelial projections into the body cavity known as diverticulae.
Kaleb Hill, Aaron H. Griffing, Michael A. Palmer, Bezia Lemma, Aria S. Lupo, Tony Gamble, Natalia A. Shylo, Andrej Košmrlj, Paul A. Trainor, Celeste M. Nelson   +9 more
wiley   +1 more source

Surgical Myectomy after Failed Ablation for Hypertrophic Obstructive Cardiomyopathy

The Thoracic & Cardiovascular Surgeon Reports, 2016
Background Hypertrophic cardiomyopathy is a genetic disease of the myocardial sarcolemma characterized by left ventricular hypertrophy. When obstruction to the left ventricular outflow tract is present and symptoms are refractory to medication, surgical ...
Ioannis Bougioukas, Uta Hoppe, Bernhard Danner, Friedrich A. Schoendube   +3 more
doaj   +1 more source